2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
Armstrong A, Blauvelt A, Mrowietz U, Strober B, Gisondi P, Merola J, Langley R, Ståhle M, Lebwohl M, Netea M, Nunez Gomez N, Warren R. A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. Dermatology And Therapy 2022, 12: 787-800. PMID: 35167107, PMCID: PMC8941045, DOI: 10.1007/s13555-022-00687-0.Peer-Reviewed Original ResearchIL-23/ILOral candidiasisImmune-mediated inflammatory skin diseaseCo-existing diabetesGood oral hygieneInflammatory skin diseaseDysregulation of cytokinesStandard antifungal therapyAntifungal host defensePlaque psoriasisBiologic therapyInterleukin-17Oral hygieneAntifungal therapyPsoriasisPatientsSkin diseasesCandidiasisHost defenseFungal infectionsCytokinesTherapyTreatmentILPractical guide
2017
Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis
Papp K, Bachelez H, Blauvelt A, Winthrop K, Romiti R, Ohtsuki M, Acharya N, Braun D, Mallbris L, Zhao F, Xu W, Walls C, Strober B. Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis. British Journal Of Dermatology 2017, 177: 1537-1551. PMID: 28600810, DOI: 10.1111/bjd.15723.Peer-Reviewed Original ResearchConceptsIncidence rateTreatment groupsInfection rateSpecific infection rateSevere psoriasisSerious infectionsExposure-adjusted incidence ratesIRs of infectionsMonoclonal antibodiesWeeks of treatmentOverall infection rateIncidence of infectionOesophageal candidiasisBiological therapyPsoriasis trialsAntifungal therapyClinical trialsIxekizumabCandida infectionsPatientsLong-term exposureInfectionPsoriasisIncidenceTrials